contramal uno 300 mg retardtablette
endo ventures - tramadol-hydrochlorid - retardtablette - 300 mg - tramadol-hydrochlorid 300 mg - tramadol
noax uno 100 mg retardtabletten
endo ventures limited - tramadolhydrochlorid - tramadol
noax uno 200 mg retardtabletten
endo ventures limited - tramadolhydrochlorid - tramadol
noax uno 300 mg retardtabletten
endo ventures limited - tramadolhydrochlorid - tramadol
testim 50 mg transdermales gel
endo ventures - testosteron - transdermales gel - 50 mg - testosteron 50 mg - testosterone
tecvayli
janssen-cilag international n.v. - teclistamab - multiples myelom - antineoplastische mittel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
lunsumio
roche registration gmbh - mosunetuzumab - lymphom, follikulär - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastische mittel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multiples myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - multiples myelom - antineoplastische mittel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.